October #blueprint notes up: New maxHR 183 bpm = age 37. +8% in 12/mo (was age 60). 23 yr age reduction. Exciting bc couldn’t get maxHR to budge for over 12/mo nor find research showing it was possible gif: same conference/stage 4 years apart
October #blueprint notes up:
New maxHR 183 bpm = age 37. +8% in 12/mo (was age 60). 23 yr age reduction. Exciting bc couldn’t get maxHR to budge for over 12/mo nor find research showing it was possible
gif: same conference/stage 4 years apart
Waist circumference measurement 82.8 cm, average for a 25 year old (maximum age reduction) BIA scale body fat% 21-23 ave BMI = to age 16 (max reduction) Improved HRV by 2%, 55 from 54 (Whoop 7 day average rMSSD deep sleep 5 min HRV)
Waist circumference measurement 82.8 cm, average for a 25 year old (maximum age reduction)
BIA scale body fat% 21-23 ave BMI = to age 16 (max reduction)
Improved HRV by 2%, 55 from 54 (Whoop 7 day average rMSSD deep sleep 5 min HRV)
@rickygervais "Anyone who isn't confused really doesn't understand the situation." ― Edward R. Murrow
@WilliamALamkin @fewocious @KernelCo Yes, as we begin to scale, there will be plenty opportunity!
My house will likely be on the skip list next #Halloween
RT @Zahra_M_Aghajan: If you: 1. are curious to learn about what @KernelCo is up to &| 2. are interested to know more about the Kernel Flow…
@rachelkellynz @bulletproofexec @LewisHowes @CarnivoreMD For #Blueprint protocol decision making, we complete a GRADE based systematic review and use an IPDAS+ decision aid before corroborating with expert clinicians and personal n=1 relevant biomarker data.
Exciting to explore the possibilities of psychedelic therapeutics by enabling longitudinal brain activity measurement before, during and after a psychedelic experience, leading to quantifying what has been subjective patient reporting.
We received FDA authorization to measure ketamine’s psychedelic effect on the brain using @kernelco Flow with our partner @CybinInc